Via Therapeutics, LLC
Publicly observedAustin, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Austin | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Via Therapeutics, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | YHRZATLXKL46 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant9 Sept 2026Publicly observed
NIH SBIR/STTR award: Development of Macrophage Targeting Inhaled Tigecycline Dry Powder Formulation for Treating Non-Tuberculous Mycobacterial (NTM) Infections
USD 313,674.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Dry powders of whole blood prepared by thin-film freeze-drying
USD 315,082.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant18 Sept 2025Publicly observed
NIH SBIR/STTR award: Combined Amikacin and Azithromycin in an Inhaled Formulation for the Treatment of NTM
USD 314,363.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant11 Sept 2025Publicly observed
NIH SBIR/STTR award: Microneedle-based mRNA Flu Vaccine for Transcutaneous Immunization
USD 314,363.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant3 Jul 2023Publicly observed
NIH SBIR/STTR award: Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza
USD 971,316.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant3 Jul 2023Publicly observed
NIH SBIR/STTR award: Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant12 Jul 2021Publicly observed
NIH SBIR/STTR award: Development of dermal targeting formulations for squamous cell carcinoma
USD 660,779.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.